lysine acetylsalicylate — Competitive Intelligence Brief

lysine acetylsalicylate (lysine acetylsalicylate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent. Area: Cardiovascular; Pain management; Inflammation.

marketed Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) Cardiovascular; Pain management; Inflammation Small molecule

Target snapshot

lysine acetylsalicylate (lysine acetylsalicylate) — Azienda Ospedaliera San Giovanni Battista. Lysine acetylsalicylate is a salt form of aspirin that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide analgesic, anti-inflammatory, and antiplatelet effects.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
lysine acetylsalicylate TARGET	lysine acetylsalicylate	Azienda Ospedaliera San Giovanni Battista	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Ibuprofen Tablets	Ibuprofen Tablets	Overseas Pharmaceuticals, Ltd.	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Diclofenac Sodium Topical Gel, 1%	Diclofenac Sodium Topical Gel, 1%	Amneal Pharmaceuticals, LLC	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Aspirin tablets	Aspirin tablets	PLx Pharma	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Ibuprofen bolus injection	Ibuprofen bolus injection	Federal Research and Clinical Centre of Intensive Care Medicine and Rehabilitology	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Diclofenac Potassium for Oral Solution	Diclofenac Potassium for Oral Solution	Depomed	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Aspirin First	Aspirin First	University of Pennsylvania	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent class)

1. Assistance Publique - Hôpitaux de Paris · 3 drugs in this class
2. Basque Health Service · 2 drugs in this class
3. PLx Pharma · 2 drugs in this class
4. Biogen · 1 drug in this class
5. Eli Lilly and Company · 1 drug in this class
6. Harbin Medical University · 1 drug in this class
7. Janssen Scientific Affairs, LLC · 1 drug in this class
8. Azienda Ospedaliera San Giovanni Battista · 1 drug in this class
9. Royal College of Surgeons, Ireland · 1 drug in this class
10. Shiraz University of Medical Sciences · 1 drug in this class